Ricky TurgeonBSc(Pharm), ACPR, PharmD
Collaboration for Outcomes Research and Evaluation (CORE)
Accepting Graduate Students
Turgeon RD, Barry AR, Hawkins NM, Ellis UM. Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis. European Journal of Heart Failure 2021 Feb 25;doi: 10.1002/ejhf.2141. PubMed ID: 33634543
Barry AR, Turgeon RD. The case for independent pharmacist prescribing. Canadian Pharmacists Journal (Ottawa) 2020;153:319-20. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689627/
Turgeon RD, Youngson E, Graham MM. Risk of Pneumonia with Ticagrelor Versus Clopidogrel: a Population-Based Cohort Study. Journal of General Internal Medicine 2020 Aug 20;doi: 10.1007/s11606-020-06131-3. PubMed ID: 32820419
Turgeon RD, Koshman SL, Youngson E, et al. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Internal Medicine 2020;180:420-8. PubMed ID: 31930361
Turgeon RD, Koshman SL, Youngson E, Pearson GJ. Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery. Pharmacotherapy 2020;40:116-24. PubMed ID: 31883378
Turgeon RD, Kolber MR, Loewen P, et al. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. PLoS One 2019;14:e0212907. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212907
Turgeon RD, Tsuyuki RT, Gyenes GT, Pearson GJ. Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. Canadian Journal of Cardiology 2018;34:1600-5. PubMed ID: 30527147
"Best Clinical Science Award." Turgeon RD. University of Alberta, Faculty of Medicine and Dentistry – Mazankowski Alberta Heart Institute 2018 Cardiac Sciences Research Day. June 2018.
“Resident Impact Award.” Turgeon RD. Lower Mainland Pharmacy Services Pharmacy Practice Residency Program. June 2013.
"Use and effectiveness of combination preventive medical therapy in patients with non-obstructive coronary artery disease." Turgeon RD (PI), Sedlak T. $5000. Vancouver Coastal Health Research Institute Research Challenge. 2019.
“The effectiveness of a standardized iron deficiency treatment protocol for ambulatory heart failure patients.” Sidsworth M, Turgeon R, Tang E, Hawkins N. $5000. Vancouver Coastal Health Research Institute Research Challenge. 2019.
New drugs (SGLT2 inhibitors) for heart failure management: Where do they fit in? The MEDS Conference 2021. Rady Faculty of Health Sciences, University of Manitoba; January 30, 2021.
Fixing Hearts without Breaking the Bank: Access to Novel ATTR Amyloidosis Therapies in Canada (speaker). Canadian Cardiovascular Congress 2020 Virtual; October 22, 2020.
How to Critically Appraise a Trial in 10 Minutes. Professional Practice Conference 2020. Toronto, ON; February 3, 2020.
Dr. Ricky Turgeon received his BSc(Pharm) in 2012 from the Dalhousie University College of Pharmacy, his ACPR from the Lower Mainland Pharmacy Services Residency Program in 2013, and his PharmD in the Faculty of Pharmaceutical Sciences at UBC in 2015. He then completed a two-year post-doctoral fellowship with Drs. Glen Pearson and Sheri Koshman at the University of Alberta Faculty of Medicine & Dentistry (Division of Cardiology) in 2018. Currently, Dr. Turgeon is assistant professor (tenure-track) at the UBC Faculty of Pharmaceutical Sciences; and clinical pharmacy specialist at St. Paul’s Hospital.
Dr. Turgeon’s research focuses on integrating high-quality observational studies and meta-analyses of clinical studies to guide the creation and evaluation of decision support tools and other knowledge translation strategies to ensure that pharmacotherapy for cardiovascular disease align with patient goals, preferences and values. His research is centered on implementation science, with a focus on antithrombotic agents, lipid-lowering therapies, pharmacotherapy for heart failure, and on the cardiovascular safety of medications.